Risk of Progression of High-grade Primary T1 Non-muscle-invasive Bladder cancer in a Contemporary Cohort.

Autor: Pijpers OM; Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands., van Hoogstraten LMC; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Remmers S; Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands., Beijert IJ; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Oddens JR; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands., Alfred Witjes J; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands., Kiemeney LA; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands., Aben KKH; Department of Research and Development, Netherlands Comprehensive Cancer Organization, Utrecht, The Netherlands; IQ Health Science Department, Radboud University Medical Center, Nijmegen, The Netherlands., Boormans JL; Department of Urology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands. Electronic address: j.boormans@erasmusmc.nl.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Sep 25. Date of Electronic Publication: 2024 Sep 25.

A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.

Autor: de Jong JJ; Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands. Electronic address: j.j.dejong@erasmusmc.nl., Pijpers OM; Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands., van Kessel KEM; Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands., Boormans JL; Department of Urology, Erasmus MC Urothelial Cancer Research Group, Rotterdam, The Netherlands., Van Criekinge W; Laboratory of Bioinformatics and Computational Genomics, Ghent University, Ghent, Belgium., Zwarthoff EC; Department of Pathology, Erasmus University Medical Center, Rotterdam, The Netherlands., Lotan Y; Department of Urology, UT Southwestern Medical Center, Dallas, TX, USA.

Publikováno v: European urology oncology [Eur Urol Oncol] 2023 Apr; Vol. 6 (2), pp. 183-189. Date of Electronic Publication: 2022 Sep 08.

Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.

Autor: Pijpers OM; Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Hendricksen K; Department of Surgical Oncology, Division of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Mostafid H; Department of Urology, Royal Surrrey County Hospital, Guildford, United Kingdom., de Jong FC; Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Rosier M; Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Mayor N; Department of Urology, Royal Surrrey County Hospital, Guildford, United Kingdom., de Jong JJ; Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands., Boormans JL; Department of Urology, Erasmus MC Cancer Institute, Erasmus Medical Center, Rotterdam, The Netherlands. Electronic address: j.boormans@erasmusmc.nl.

Publikováno v: Urologic oncology [Urol Oncol] 2022 Feb; Vol. 40 (2), pp. 62.e13-62.e20. Date of Electronic Publication: 2021 Aug 30.